Shareholders to Vote on Reverse Stock Split, Massive Share Increase, and New Equity Plans

summarizeSummary

Interpace Biosciences is seeking shareholder approval for a reverse stock split, a significant increase in authorized shares, and new equity compensation plans, all critical steps for potential Nasdaq uplisting but carrying substantial dilution risk.

check_boxKey Events · Corporate Governance and Compliance · IDXG

• Reverse Stock Split Proposal

  Shareholders will vote on a reverse stock split in a range of 1-for-2 to 1-for-10, primarily to meet Nasdaq listing requirements. This follows a PRE 14A filing on June 23, 2026, which first disclosed this proposal.

• Massive Increase in Authorized Shares

  Proposal to increase authorized common stock by 100,000,000 shares (from 100M to 200M), creating significant headroom for future capital raises and potential dilution. If all authorized shares were issued, dilution would be approximately 360.9%.

• New Equity Incentive Plan

  Proposal for a 2026 Equity Incentive Plan reserving 4,400,000 shares, representing approximately 15.88% potential dilution of current outstanding shares.

• New Employee Stock Purchase Plan

  Proposal for a 2026 Employee Stock Purchase Plan reserving 1,000,000 shares, representing approximately 3.61% potential dilution of current outstanding shares.

auto_awesomeAnalysis · IDXG · Industrial Applications And Services

This definitive proxy statement outlines critical proposals for the upcoming annual meeting, including a reverse stock split (1-for-2 to 1-for-10) aimed at Nasdaq uplisting, a 100% increase in authorized common shares (from 100M to 200M), and new equity incentive and employee stock purchase plans that could collectively dilute existing shareholders by approximately 19.5%. These measures are designed to facilitate uplisting and provide capital flexibility, but introduce substantial potential for future dilution, following a preliminary proxy filing on June 23, 2026.